The PAN Foundation and the International Waldenstrom’s Macroglobulinemia Foundation today announced they are launching a new partnership to offer a broad range of support for people living with Waldenstrom’s macroglobulinemia.
Working together, the PAN Foundation and the International Waldenstrom’s Macroglobulinemia Foundation will ensure that people living with Waldenstrom’s macroglobulinemia have access to both financial and patient support services, providing them with comprehensive resources needed to best manage their condition.
“Waldenstrom’s macroglobulinemia is a chronic disease, which may require years of treatment, resulting in years of high out-of-pocket costs,” said PAN President and CEO Dan Klein. “We are thrilled to begin this partnership with the International Waldenstrom’s Macroglobulinemia Foundation, so that in addition to PAN’s co-pay support, we will be able to provide our patients living with this rare disease additional resources and opportunities find community as they manage symptoms.”
Waldenstrom’s macroglobulinemia is a rare type of blood cancer that originates in the lymphatic system and is characterized by an excess of abnormal white blood cells and proteins called immunoglobulins. The American Cancer Society estimates that 1,500 people are diagnosed with Waldenstrom’s macroglobulinemia each year in the United States.
“Our mission is to advance the search for a cure, and until that happens, to support and educate every person who is affected by Waldenstrom’s macroglobulinemia,” said International Waldenstrom’s Macroglobulinemia Foundation President and CEO Newton Guerin. “Our organization was founded by patients seeking support and information. Our alliance with the PAN Foundation will extend that support, and our shared resources will increase the number of patients who are able to get help paying high out-of-pocket costs for treatment for this rare disease.”
Patients who qualify for the PAN Foundation’s Waldenstrom’s macroglobulinemia assistance fund are eligible to receive $5,000 per year in financial assistance.
To get financial assistance for Waldenstrom’s macroglobulinemia, patients must:
- Be getting treatment for Waldenstrom’s macroglobulinemia.
- Have Medicare health insurance that covers the qualifying medication or product.
- Have an income that falls at or below 500% of the Federal Poverty Level.
How to apply
Patients, caregivers or advocates applying on their behalf can apply for assistance using the PAN Foundation’s online patient portal.
About the PAN Foundation
The PAN Foundation is an independent, nationwide 501(c)(3) organization dedicated to providing help and hope to underinsured patients who are unable to afford the out-of-pocket expenses for their prescribed medications. Since 2004, PAN has provided over $3 billion in financial assistance to nearly 1 million patients who would otherwise be unable to afford their medications. To learn more, visit www.panfoundation.org.
About the International Waldenstrom’s Macroglobulinemia Foundation
The International Waldenstrom’s Macroglobulinemia Foundation (IWMF) is a patient-founded and patient-led international nonprofit organization with a simple but compelling vision and mission.
VISION: A world without WM (Waldenstrom’s macroglobulinemia)
MISSION: Support and educate everyone affected by Waldenstrom’s macroglobulinemia (WM) while advancing the search for a cure.
The IWMF is committed to creating a world without WM by finding a cure. Since 1999, the IWMF has invested over $18 million in WM research projects throughout the world. Thanks to this research WM patients have better treatment options that can lead to deeper, longer-lasting remissions, and fewer side effects.
Liz Eckert, Director of Marketing and Communications
Was this helpful?